Veru looks to have increased its attractiveness as a potential partner or buyout in the obesity space with its latest data readout. The company’s oral selective androgen receptor modulator (SARM), enobosarm, has been shown to promote weight loss and preserve lean muscle mass even after a patient discontinues treatment with a GLP-1 agonist.
Key Takeaways
Veru hopes to get the Phase III trial for enobosarm underway in the first quarter of 2026.
The company is in discussions with potential partners.
Veru expects cash on hand ($20m as of March 2025) to last till the end of the year.
The Miami, FL-based biotech has produced a series of positive data readouts for enobosarm as the company gets closer to...